| January 2 |
2008 - The Year in Drugs |
| January 2 |
MedWatch - Innohep (tinzaparin sodium) Dear Healthcare Professional Letter Issued Re: Increased Risk of Death in Renal Impaired Elderly |
| January 2 |
Study is Among First to Link Short Term Drug Use for Osteoporosis to Bone Death |
| January 2 |
AMSA Applauds Pharma Ban; Continues to Call for Federal Regulation |
| January 5 |
Daiichi Sankyo Records Valuation Loss, Goodwill Write-down, on Investment in Ranbaxy Laboratories |
| January 5 |
PPD Enters Into Strategic Collaboration with Merck |
| January 5 |
Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals |
| January 5 |
Adventrx Announces Further Cost-Cutting Measures |
| January 6 |
Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis |
| January 6 |
HealthCentral Amasses Top Three Online Health Audience; Study Reveals More Consumers Turned to Internet for Health Info Than Their Physician Last Year |
| January 6 |
CMS Reports Lowest Rate of Overall Growth in National Health Spending Since 1998 |
| January 6 |
Advaxis' Phase II Clinical Trial “HOLD” Lifted |
| January 6 |
If You Take Erectile Dysfunction Medications, Read This List |
| January 7 |
Orion's Statutory Negotiations Completed. Personnel to be Reduced by About 205 in Finland |
| January 7 |
Daiichi Sankyo, Inc. Establishes Subsidiary in Puerto Rico |
| January 7 |
Sangart, Inc. Announces Key Executive Appointments and Company Restructuring |
| January 7 |
Bio-Imaging Technologies Sells CapMed Division to Metavante Technologies |
| January 7 |
Crucell and Wyeth in Discussion on a Combination of the Two Companies |
| January 8 |
Plexxikon and Roche Enter Second Partnership to Develop PLX5568 for Polycystic Kidney Disease |
| January 8 |
ICON plc Acquires Remaining 30% Stake in Beacon Bioscience Inc. |
| January 8 |
Hormone Therapy Associated With Reduced Colorectal Cancer Risk |
| January 9 |
Update of Safety Review Follow-up to the January 25, 2008 Early Communication about an Ongoing Data Review for Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor) |
| January 9 |
UCB and Wilex to Enter Into Strategic Alliance to Develop UCB's Preclinical Oncology Portfolio |
| January 12 |
EpiCept Discontinues Drug Discovery Operations and Reduces Workforce |
| January 12 |
FDA Awaits Court's Entry of A Permanent Injunction Against Actavis Totowa, LLC |
| January 12 |
Abbott Announces Earnings Guidance for 2009 |
| January 12 |
Pfizer Contributes Critical Data to URMC Drug Safety Initiative |
| January 13 |
FDA Announces Two Appointments |
| January 13 |
Elan to Review Strategic Business Alternatives |
| January 13 |
Bristol-Myers Squibb and ZymoGenetics Enter Global Collaboration on Novel Hepatitis C Compound |
| January 13 |
Merck KGaA and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis |
| January 13 |
Genzyme Reports Strong Fourth-Quarter and 2008 Revenue Growth |
| January 13 |
Update of Safety Review Follow-up to the March 27, 2008, Communication about the Ongoing Safety Review of Montelukast (Singulair) |
| January 14 |
Merck Statement in Response to the FDA's Update Regarding a Safety Review of Singulair (montelukast) |
| January 14 |
Almost Three-Quarters (70%) of Online Canadians Have Visited a Healthcare Website in the Past Year |
| January 14 |
Use of Antidepressants Associated With Improvement in Symptoms of Fibromyalgia |
| January 14 |
Sen. Grassley Comments on FDA Tracking of Clinical Investigators’ Financial Ties |
| January 14 |
Nycomed Strengthens its Osteoporosis Portfolio |
| January 14 |
FDA Launches Pilot Program To Improve the Safety of Drugs and Active Drug Ingredients Produced Outside the United States |
| January 14 |
New Analysis Estimates Numbers of Older U.S. Adults Who May Benefit From Statin Therapy |
| January 15 |
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices |
| January 15 |
Bionovo Announces Cost Control Measures Taken |
| January 15 |
Use of Atypical Antipsychotic Drugs Increases Risk of Sudden Cardiac Death in Adults |
| January 15 |
US Department of Health and Human Services Awards Novartis $486 Million Contract to Build Manufacturing Facility for Pandemic Flu Vaccine |
| January 15 |
Former Johnson & Johnson Executive Gives Big Voice to Small Companies |
| January 15 |
Johnson & Johnson Announces Satisfaction of Regulatory Clearances Condition for its Proposed Acquisition of Mentor Corporation |
| January 16 |
XOMA Announces Workforce Reduction |
| January 16 |
Genentech Announces Full Year and Fourth Quarter 2008 Results |
| January 20 |
Abbott Opens New Pharmaceutical Research Laboratory in Singapore |
| January 20 |
Physician Social Networkers are High Prescribers and More Likely to Engage with Pharma |
| January 20 |
Forest Laboratories, Inc. Reports Q3'09 Diluted Earnings Per Share of $0.62, Including $0.41 Per Share Charge for New Product Licensing Fees |
| January 20 |
Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results |
| January 20 |
Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program |
| January 20 |
FDA Alerts Public about Danger of Skin Numbing Products |
| January 20 |
Teva and Lonza Announce Strategic Partnership to Become a Leading Global Provider of Biosimilars |
| January 20 |
Johnson & Johnson Completes Initial Tender Offer for Mentor Corporation with 92.9% of Shares Tendered |
| January 21 |
Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings |
| January 21 |
Medication May Provide Some Benefit for Older Adults With Anxiety Disorder |
| January 22 |
European Physician Tech Tools of the Trade - Wikipedia and Social Networking? |
| January 22 |
Biovitrum (SE) - Biovitrum aims to spin-out Cambridge Biotechnology |
| January 22 |
Akesis Pharmaceuticals Discontinues Sole Clinical Development Program and Announces Intent to File for Chapter 7 Bankruptcy |
| January 22 |
Novartis Launches Extavia, A New Therapeutic Option To Help Patients Combat Devastating Symptoms Of Multiple Sclerosis |
| January 22 |
Enlight Biosciences Expands to Direct up to $52 Million to Transformational Enabling Technologies |
| January 23 |
UCB to Divest Selected Smaller Markets to Further Focus on its Key Strategic Areas |
| January 23 |
Report: Pfizer May Buy Wyeth for $60 Billion |
| January 23 |
XTENT to Retain Investment Bank to Pursue Strategic Alternatives |
| January 23 |
GAO: High-Risk Series: An Update |
| January 23 |
Grassley Works to Disclose Financial Ties Between Drug Companies and Doctors |
| January 23 |
Penwest Sets Focused Priorities for 2009; Takes Actions to Further Reduce Costs |
| January 23 |
Lexicon Consolidates Operations to Focus Resources on Most Advanced Drug Discovery and Development Programs |
| January 23 |
Geron Receives FDA Clearance to Begin World's First Human Clinical Trial of Embryonic Stem Cell-Based Therapy |
| January 26 |
Pfizer to Acquire Wyeth, Creating the World's Premier Biopharmaceutical Company |
| January 26 |
Pfizer Reports Fourth-Quarter and Full-Year 2008 Results and 2009 Financial Guidance |
| January 26 |
Crucell N.V. (NL) - Discussions on a Combination of Crucell and Wyeth Discontinued |
| January 26 |
Pfizer to Acquire Wyeth, Creating the World's Premier Biopharmaceutical Company |
| January 26 |
MEDIA ADVISORY: Pfizer and Wyeth to Host Live Press Conference in New York |
| January 26 |
Administrative Law Judge Upholds HHS-OIG Exclusions Imposed Against Responsible Corporate Officers in OxyContin Case |
| January 26 |
Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter |
| January 26 |
Substantial Increase in Public Preference for Generic over Brand Name Drugs |
| January 26 |
Altus Pharmaceuticals Realigns Product Development Priorities and Focuses on Long-Acting Growth Hormone Candidate ALTU-238 |
| January 26 |
KV Pharmaceutical Suspends Product Manufacturing, Shipping |
| January 27 |
Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 |
| January 27 |
FDA Issues an Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix) |
| January 27 |
Strong Fourth Quarter Supports Excellent 2008 for Bristol-Myers Squibb |
| January 27 |
Astellas Proposes to Acquire CV Therapeutics for $16 Per Share in Cash |
| January 27 |
Manhattan Research Survey Finds That Physicians Overwhelmingly Support Commercially-Funded Continuing Medical Education |
| January 27 |
Verified Physicians a Must for Ensuring Quality Data From Online Surveys, Finds Frost & Sullivan |
| January 28 |
CV Therapeutics Statement on Unsolicited Proposal From Astellas |
| January 28 |
Sequenom Terminates Exchange Offer to Acquire EXACT Sciences |
| January 28 |
Roche Delighted About Pool Extension |
| January 28 |
Strong Fourth Quarter Supports Excellent 2008 for Bristol-Myers Squibb |
| January 28 |
Gilead Sciences Announces Record Fourth Quarter and Full Year 2008 Financial Results |
| January 28 |
Pharmaceutical eNewsletters Launch “XTRA” Content |
| January 29 |
Lilly Reports Fourth-Quarter and Full-Year 2008 Results |
| January 29 |
AstraZeneca PLC - Fourth quarter and Full Year Results 2008 |
| January 29 |
Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update |
| January 29 |
Sepracor Announces Strategic Corporate Restructuring and Workforce Reduction Plan in Addition to 2009 Financial Guidance |
| January 29 |
Med Ad News’ 20th Annual Manny Awards Will Honor Healthcare Advertising Agencies |
| January 29 |
Actelion Pharmaceuticals Ltd (CH) - Zavesca (miglustat) receives EU approval for the treatment of progressive neurological manifestations in patients with Niemann-Pick type C disease |
| January 29 |
Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration |
| January 29 |
Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato Loxapine) for Acute Agitation |
| January 30 |
Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash |
| January 30 |
FDA Sends Abbott Letter Regarding Depakote ER/Depakote Continuum Care Pharmacy Formulary Flashcard |
| January 30 |
Lilly Announces Senior Leadership Change |
| January 30 |
Kyowa Hakko Kirin Third Quarter Results; Revision of Full Year Forecasts; Planned Change of Fiscal Year End |
| January 30 |
Major Shareholders Criticize Enzon Pharmaceuticals Management Team in Open Letter |
| January 30 |
Special Committee of Genentech Board of Directors Responds to Roche's Announced Intention to Commence a Tender Offer |
